Oral Apolipoprotein A-I Mimetic D-4F Lowers HDL-Inflammatory Index in High-Risk Patients: A First-in-Human Multiple-Dose, Randomized Controlled Trial.

about

Method to generate highly stable D-amino acid analogs of bioactive helical peptides using a mirror image of the entire PDB.

P2860

Q48147689-5E1908B7-79AB-402E-A345-454CB5C07C85

P2860

Oral Apolipoprotein A-I Mimetic D-4F Lowers HDL-Inflammatory Index in High-Risk Patients: A First-in-Human Multiple-Dose, Randomized Controlled Trial.

Item

http://www.wikidata.org/entity/Q46350113

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Oral Apolipoprotein A-I Mimeti ...... , Randomized Controlled Trial.

@en

Oral Apolipoprotein A-I Mimeti ...... , Randomized Controlled Trial.

@nl

type

Item

label

Oral Apolipoprotein A-I Mimeti ...... , Randomized Controlled Trial.

@en

Oral Apolipoprotein A-I Mimeti ...... , Randomized Controlled Trial.

@nl

prefLabel

Oral Apolipoprotein A-I Mimeti ...... , Randomized Controlled Trial.

@en

Oral Apolipoprotein A-I Mimeti ...... , Randomized Controlled Trial.

@nl

P1476

Oral Apolipoprotein A-I Mimeti ...... , Randomized Controlled Trial.

@en

P2093

Alan M Fogelman

http://www.w3.org/2001/XMLSchema#string

Daniel J Rader

http://www.w3.org/2001/XMLSchema#string

Danielle Duffy

http://www.w3.org/2001/XMLSchema#string

LeAnne T Bloedon

http://www.w3.org/2001/XMLSchema#string

Mohamad Navab

http://www.w3.org/2001/XMLSchema#string

Rajesh Movva

http://www.w3.org/2001/XMLSchema#string

Richard L Dunbar

http://www.w3.org/2001/XMLSchema#string

Robert B Norris

http://www.w3.org/2001/XMLSchema#string

P2860

HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis

Coronary artery disease in patients at low risk--apolipoprotein AI as an independent risk factor.

In vivo efficacy of HDL-like nanolipid particles containing multivalent peptide mimetics of apolipoprotein A-I.

Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function.

Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally.

D-4F-mediated reduction in metabolites of arachidonic and linoleic acids in the small intestine is associated with decreased inflammation in low-density lipoprotein receptor-null mice

Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures

Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse.

Apolipoprotein A-I mimetic peptides.

Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients.

P304

455-469

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CTS.12487

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28795506

http://www.w3.org/2001/XMLSchema#string

P932

5673907

http://www.w3.org/2001/XMLSchema#string

Oral Apolipoprotein A-I Mimetic D-4F Lowers HDL-Inflammatory Index in High-Risk Patients: A First-in-Human Multiple-Dose, Randomized Controlled Trial.

about

P2860

P2860

Oral Apolipoprotein A-I Mimetic D-4F Lowers HDL-Inflammatory Index in High-Risk Patients: A First-in-Human Multiple-Dose, Randomized Controlled Trial.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932